Allison MD - Prometheus Biosciences Chief Officer
Insider
Allison MD is Chief Officer of Prometheus Biosciences
| Age | 50 |
| Phone | 858 684 1300 |
| Web | https://www.prometheusbiosciences.com |
Prometheus Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.2006) % which means that it has lost $0.2006 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.333) %, meaning that it created substantial loss on money invested by shareholders. Prometheus Biosciences' management efficiency ratios could be used to measure how well Prometheus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Prometheus Biosciences currently holds 14.76 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Prometheus Biosciences has a current ratio of 13.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Prometheus Biosciences' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Bill DeGrado | Pliant Therapeutics | N/A | |
| Craig Muir | Pliant Therapeutics | N/A | |
| Rebecca MD | Madrigal Pharmaceuticals | 73 | |
| David Tice | Arcellx | 53 | |
| Alexis AM | Blueprint Medicines Corp | 53 | |
| Narinderjeet MS | Arcellx | 53 | |
| Tom Holmes | Amylyx Pharmaceuticals | N/A | |
| Mike Ouimette | Pliant Therapeutics | 51 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Richard Pulik | Roivant Sciences | 45 | |
| Huafeng Xu | Roivant Sciences | N/A | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| ric MD | Pliant Therapeutics | 60 | |
| FACC MD | Stoke Therapeutics | 61 | |
| Paul MD | Madrigal Pharmaceuticals | 81 | |
| Johannes Hull | Pliant Therapeutics | 50 | |
| Christopher MD | Arcellx | 45 | |
| Debra Canner | Amylyx Pharmaceuticals | 65 | |
| Katherine Tuminello | Krystal Biotech | N/A | |
Management Performance
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 |
Prometheus Biosciences Leadership Team
Elected by the shareholders, the Prometheus Biosciences' board of directors comprises two types of representatives: Prometheus Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prometheus. The board's role is to monitor Prometheus Biosciences' management team and ensure that shareholders' interests are well served. Prometheus Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prometheus Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Allison MD, Chief Officer | ||
| Noel Kurdi, VP Communications | ||
| Timothy Esq, G Sec | ||
| Chris Doughty, Chief Officer | ||
| Mark McKenna, CEO Pres | ||
| Nori Ebersole, Chief Officer | ||
| Olivier Laurent, Chief RD | ||
| MBA MBA, Chief Officer | ||
| Mark Stenhouse, Chief Officer |
Prometheus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prometheus Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (40.65) % | |||
| Current Valuation | 4.39 B | |||
| Shares Outstanding | 47.81 M | |||
| Shares Owned By Insiders | 16.61 % | |||
| Shares Owned By Institutions | 81.01 % | |||
| Number Of Shares Shorted | 4.68 M | |||
| Price To Earning | (5.66) X | |||
| Price To Book | 19.88 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Prometheus Stock
If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |